Valuation: biote Corp.

Market Cap 73.71M 64.51M 59.59M 54.83M 103M 7.1B 106M 713M 280M 3.48B 277M 271M 11.98B P/E 2026 *
10.3x
P/E 2027 * 6.75x
Enterprise Value 160M 140M 129M 119M 224M 15.36B 229M 1.54B 606M 7.52B 599M 586M 25.93B EV / Sales 2026 *
0.84x
EV / Sales 2027 * 0.71x
Free-Float
85.15%
Yield 2026 *
-
Yield 2027 * -
1 day+2.10%
1 week+4.29%
Current month+28.57%
1 month+7.52%
3 months+9.46%
6 months+4.74%
Current year-6.54%
1 week 2.1
Extreme 2.1002
2.53
1 month 1.63
Extreme 1.63
2.53
Current year 1.27
Extreme 1.27
2.68
1 year 1.27
Extreme 1.27
4.75
3 years 1.27
Extreme 1.27
8.44
5 years 1.27
Extreme 1.27
10.52
10 years 1.27
Extreme 1.27
10.52
Manager TitleAgeSince
Chief Executive Officer 49 2026-06-11
Chief Tech/Sci/R&D Officer 69 2024-02-29
Sales & Marketing - -
Director TitleAgeSince
Chairman 61 2022-04-30
Director/Board Member 51 2022-04-30
Director/Board Member 63 2022-04-30
Date Insider Type Main position Quantity % Market Cap.
6/12/26 Free

Chief Executive Officer

206,746 0.6816%
6/8/26 Free

Chief Executive Officer

130,000 0.4286%
6/8/26 Free

Chairman

114,157 0.3764%
Change 5-day change 1-year change 3-year change Capi.($)
+2.10%+4.29%-39.55%-68.73% 73.71M
-.--%-.--%-.--%+96.00% 1.48B
-1.57%-3.47%-22.00%+21.28% 138M
+4.70%-4.38%-41.71%-91.49% 91.37M
0.00%0.00%+6.84%+8.70% 61.65M
+2.86%+0.52%-61.20%-62.11% 52.07M
Average +1.35%-0.51%-26.27%-16.06% 315.46M
Weighted average by Cap. +0.27%-0.28%-6.62%+67.88%

Financials

2026 *2027 *
Net sales 191M 167M 154M 142M 267M 18.35B 273M 1.84B 724M 8.99B 716M 700M 30.98B 205M 179M 165M 152M 287M 19.69B 293M 1.98B 777M 9.65B 768M 751M 33.25B
Net income 8.52M 7.46M 6.89M 6.34M 11.94M 820M 12.21M 82.38M 32.35M 402M 31.99M 31.29M 1.38B 12.82M 11.22M 10.36M 9.53M 17.96M 1.23B 18.37M 124M 48.66M 604M 48.12M 47.07M 2.08B
Net Debt 85.86M 75.14M 69.42M 63.86M 120M 8.27B 123M 830M 326M 4.05B 322M 315M 13.95B 71.8M 62.84M 58.06M 53.41M 101M 6.91B 103M 694M 273M 3.39B 270M 264M 11.67B
Logo biote Corp.
biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
Employees
223
Date Price Change Volume
26-07-17 US$2.430 +2.10% 298,393
26-07-16 US$2.380 +9.68% 320,624
26-07-15 US$2.170 -0.91% 261,008
26-07-14 US$2.190 -5.60% 193,985
26-07-13 US$2.320 -0.43% 185,628
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.430USD
Average target price
2.732USD
Spread / Average Target
+12.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BTMD Stock